Pine River Capital Management’s Lisata Therapeutics LSTA Stock Holding History

Pine River Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-83,333	Closed	-$22K	–	421
2016 Q3	$22K	Buy	83,333 +74,125	+805%	+$5.97M	﹤0.01%	390
2016 Q2	$0	Hold	9,208	–	–	﹤0.01%	513
2016 Q1	$0	Hold	9,208	–	–	﹤0.01%	736
2015 Q4	$0	Sell	9,208 -1,000	-10%	-$184K	﹤0.01%	709
2015 Q3	$0	Hold	10,208	–	–	﹤0.01%	686
2015 Q2	$1K	Buy	10,208 +6,666	+188%	+$2.48M	﹤0.01%	669
2015 Q1	$1K	Hold	3,542	–	–	﹤0.01%	593
2014 Q4	$7K	Hold	3,542	–	–	﹤0.01%	692
2014 Q3	$25K	Hold	3,542	–	–	﹤0.01%	952
2014 Q2	$49K	Buy	+3,542	New	+$3.44M	﹤0.01%	681
2014 Q1	–	Sell	-2,542	Closed	-$46K	–	688
2013 Q4	$46K	Buy	+2,542	New	+$2.51M	﹤0.01%	628

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pine River Capital Management's LSTA Position: Q4 2016 in Review

Pine River Capital Management sold out of Lisata Therapeutics (LSTA) in Q4 2016, closing a stake of 83,333 shares — an estimated $22K sold.

Pine River Capital Management first reported a position in LSTA in Q4 2013 and held it in 11 quarters. The position peaked at $49K in Q2 2014. 30 funds tracked by Wall St. Rank hold LSTA as of Q4 2016.

Pine River Capital Management reported no remaining Lisata Therapeutics position as of Q4 2016 after selling out during the quarter.
Pine River Capital Management sold 83,333 Lisata Therapeutics shares in Q4 2016, an estimated $22K.
Pine River Capital Management first reported a position in Lisata Therapeutics in Q4 2013 and held it in 11 quarters.
Pine River Capital Management's Lisata Therapeutics position peaked at $49K in Q2 2014.
30 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2016.

Based on Pine River Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.